



## PRESS RELEASE

# First-in-man implantation of CARMAT's bioprosthetic artificial heart

**Paris, December 20, 2013**

CARMAT (FR0010907956, ALCAR), the designer and developer of the world's most advanced total artificial heart project, providing an alternative for people suffering from end-stage heart failure, announces the first implantation of its artificial heart, as part of its feasibility study and in accordance with the approvals granted by the ANSM (*Agence nationale de sécurité du médicament et des produits de santé*, the French health authority) and the *Comité de Protection des Personnes* (ethics committee).

The procedure was performed on December 18, 2013 by the Georges Pompidou European Hospital team in Paris (France) - a world first.

The implantation went smoothly, with the prosthesis automatically providing blood flow at physiologic conditions. The patient is currently being monitored in the intensive care unit. He is awake and talks with his family.

*"We are delighted with this first implant, although it is premature to draw conclusions given that a single implant has been performed and that we are in the early postoperative phase"*, says Marcello Conviti, Chief Executive Officer of CARMAT.

**About CARMAT: the world's most advanced total artificial heart project.**

**The only credible response for all cases of end-stage heart failure, which is a real public health issue:** CARMAT's aim is to be able to provide a response to a major public health issue associated with heart disease, the world's leading cause of death: chronic and acute heart failure. Indeed, this disease currently affects over 100 million patients in developed countries. By pursuing the development of its total artificial heart, CARMAT intends to overcome the well-known shortfall in heart transplants for the tens of thousands of people suffering from heart failure.

**The result of combining two types of unique expertise:** the medical expertise of Professor Carpentier, known throughout the world for inventing Carpentier-Edwards® heart valves, which are the most used in the world, and the technological expertise of EADS, world aerospace leader.

**Imitating the natural heart:** given its size, the choice of structural materials and its innovative physiological functions, CARMAT's total artificial heart could, assuming upcoming clinical trials are successful, potentially benefit the lives of tens of thousands of patients a year whilst ensuring there is no risk of rejection and providing them with an unparalleled quality of life.

**A project leader acknowledged at a European level:** with the backing of the European Commission, CARMAT has been granted the largest subsidy ever given to an SME by Bpifrance; a total of €33 million.

**Strongly committed, prestigious founders and shareholders:** [Truffle Capital](#), a leading European venture capital firm, [EADS](#), the [Fondation Alain Carpentier](#), the [Centre Chirurgical Marie Lannelongue](#), and the thousands of institutional and individual shareholders who have placed their trust in CARMAT.

**For more information:** [www.carmatsa.com](http://www.carmatsa.com)

...

## Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a solicitation of an offer to buy or subscribe to, shares in CARMAT ("the Company") in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based solely on the current expectations and assumptions of the Company's management and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. The Company's objectives as mentioned in this press release may not be achieved for any of these reasons or due to other risks and uncertainties.

No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the *Document de Référence* registered with *the Autorité des Marchés Financiers* under number R.13-027 on May 30, 2013 and the *Note d'Opération* that was approved with visa no. 11-308 on July 11, 2011, changes in economic conditions, the financial markets or the markets in which Carmat operates. In particular, no guarantee can be given concerning the Company's ability to finalize the development, validation and industrialization of the prosthesis and the equipment required for its use, to manufacture the prostheses, satisfy the requirements of the ANSM, enroll patients, obtain satisfactory clinical results, perform the clinical trials and tests required for CE marking and to obtain the CE mark.

•••

**CARMAT**  
Marcello Conviti - CEO

Patrick Coulombier - COO

Valerie Leroy - Director of Marketing  
& Investor Relations  
Tel. : +33 139 456450  
[contact@carmatsas.com](mailto:contact@carmatsas.com)

**Alize RP**  
Press relations  
**Caroline Carmagnol**  
**Christian Berg**

+33 170 225386  
[caroline@alizerp.com](mailto:caroline@alizerp.com)  
[christian@alizerp.com](mailto:christian@alizerp.com)

**NewCap**  
Financial communication  
and investor relations  
**Dušan Orešanský /**  
**Emmanuel Huynh**

Tel.: +33 144 719494  
[carmat@newcap.fr](mailto:carmat@newcap.fr)



Name: **CARMAT**  
ISIN code: **FR0010907956**  
Ticker: **ALCAR**